Peter Attia MD#102–Michael Osterholm, PhD: COVID-19—Challenges ahead & reasons for optimism and concern
CHAPTERS
- 0:11 – 9:56
Where We Stand: Early Predictions and the Path Ahead
Peter Attia asks Michael Osterholm what he is more or less optimistic about compared with three weeks earlier. Osterholm recounts his team's early forecasts and explains why he doubts seasonality will stop the virus. He lays out the choice between suppression, uncontrolled spread, or a middle path.
- •Osterholm's group predicted a pandemic on January 20, almost two months before the WHO
- •SARS and MERS offer little support for the idea that the virus will fade with seasons
- •Influenza pandemics have started in every season and peaked about six months after emerging
- •Suppression means a Wuhan-style shutdown, while letting it spread risks collapsing healthcare systems
- 9:56 – 14:56
Projected Spread and Evidence for Durable Immunity
Osterholm explains the scale of potential US infections and deaths if the virus keeps spreading until enough people are immune. He cites a macaque study as good news for short-term immunity. Attia adds his 'what you have to believe' framing about worst-case scenarios.
- •Infecting 60% of roughly 300 million Americans implies tens of millions of illnesses and potentially millions of deaths
- •Transmission continues in China months after the draconian measures
- •A macaque study showed protection against re-challenge a month later, confirmed by culture as well as PCR
- •Attia argues a species-ending scenario would require no immunity, worsening reinfections and no treatments
- 14:56 – 24:32
Case Fatality Rate: Numerators, Denominators and Comorbidities
Attia raises a Lancet paper revising China's case fatality rate downward, and Osterholm explains why the numerator matters more than the denominator. They discuss how smoking, obesity, renal disease and nursing homes shape CFR by country. Osterholm estimates a US CFR of 1 to 2.5%.
- •Uncounted deaths outside hospitals in Wuhan could shift the CFR sharply
- •Smoking among older Chinese men may have affected outcomes there, while obesity affects younger Americans
- •Korea and Italy differ because of age mix
- •Osterholm calls a CFR of 0.1% a pipe dream and expects 1 to 2.5%
- •Attia notes that this implies more US deaths than all other causes combined
- 24:32 – 29:53
What Must Be True to Stay Under 100,000 Deaths
Attia asks what would need to happen to keep US deaths below 100,000. Osterholm argues that full suppression is unsustainable and that failing healthcare capacity would accelerate deaths. He highlights a supply chain problem with critical generic drugs made abroad.
- •Osterholm says a Wuhan-like shutdown is not sustainable and that it is not a choice between lives and the economy
- •Essential workers must keep the country running
- •His center identified 156 critical acute-care drugs, all generic and mostly made outside the US
- •Spreading cases out over time would let hospitals cope, but he doubts it can be done
- 29:53 – 39:37
PPE Shortages and Protecting Healthcare Workers
Osterholm discusses aerosol transmission, the N95 shortfall and the manufacturing limits behind it. He describes options such as cohort wards, reuse of respirators and serology testing of healthcare workers. He also raises the mental health toll on them.
- •Influenza is partly transmitted by aerosols, which exist wherever droplets do
- •3M makes about 35 million N95s a month, while hundreds of millions may be needed
- •Options include large cohort wards, decontaminating and reusing N95s, and antibody testing
- •Healthcare workers face battlefield-like trauma and need support
- 39:37 – 46:03
Testing Limits and Supply Chain Constraints
Attia and Osterholm discuss the state of US testing, which is limited by reagent shortages. Osterholm expects testing to shrink rather than grow and describes syndromic surveillance as an alternative. They also discuss global competition for tests and machines.
- •Reagent supply chains, partly in China, are the main limit on PCR, antigen and serology testing
- •Minnesota's public health lab could run out of reagents within a day
- •Influenza-like illness surveillance showed COVID rising in New York before tests did
- •A new point-of-care test helps only if reagents and capacity exist
- 46:03 – 47:50
Planning Ahead in a Fast-Moving Pandemic
Attia compares the response to playing checkers rather than chess, and Osterholm notes that pandemic planning differs from regional disasters. Being later in the outbreak means fewer resources to draw on.
- •Responses tend to go where the puck is rather than where it's going
- •FEMA-style disaster response cannot be in all 50 states at once
- •Later-hit cities may find critical resources like drugs already used up
- 47:50 – 52:57
Why a Vaccine Is at Least 18 Months Away
Attia asks why no one can see a vaccine within 12 months. Osterholm cites safety concerns around antibody-dependent enhancement and a lack of manufacturing capacity. He points to the Ebola vaccine timeline.
- •Making a vaccine is easy, but making a safe and effective one is hard
- •Antibody-dependent enhancement was seen in SARS vaccine animal work and a dengue vaccine
- •Regulators will want substantial safety data for rare side effects
- •Little idle manufacturing capacity exists, and the Ebola vaccine took almost four years
- •Osterholm estimates 18 months at the earliest
- 52:57 – 56:55
Antivirals, Therapeutics and Lessons from Ebola
Attia notes how few antivirals have been approved in decades and links this to the strength of T cell immunity. Osterholm cautions against assuming drugs work, citing ZMapp in Ebola. He notes uncertainty about whether chloroquine suits every disease picture.
- •Only about 90 antivirals approved over roughly 55 to 60 years, with about 40 for HIV
- •ZMapp was assumed effective but did not finish in the top five drugs in a randomized trial
- •Different drugs act on different mechanisms, and some could cause harm in certain presentations
- •Answers on COVID therapeutics are far from settled
- 56:55 – 1:01:37
Long-Term Effects, Comorbidities and Differences from Influenza
Attia asks what SARS and MERS reveal about survivors, and Osterholm says little is known about residual harm. They discuss diabetes, immune compromise and why children behave differently from influenza.
- •Little data exist on long-term morbidity in SARS survivors
- •No MERS reinfection has been noted among people returning to infected herds since 2012
- •Why certain comorbidities predispose to bad outcomes remains unclear
- •Children appear infected at similar rates but show few symptoms, unlike influenza
- 1:01:37 – 1:08:10
R0, Super-Spreaders and Pre-Symptomatic Transmission
Attia asks whether R0 should be split by symptomatic status. Osterholm argues R0 is a poor fit when super-spreaders matter and describes the Seattle choir and Munich virus-level data. He favors the term pre-symptomatic and notes super-spreader traits remain unknown.
- •R0 averages mask super-spreading events like the Samsung Medical Center outbreak
- •The Seattle choir cluster illustrates a SARS-like super-spreader event
- •Munich data showed very high throat virus levels at the first symptoms
- •Aerosols are produced by talking and breathing
- •Characteristics of super-spreaders are still unknown
- 1:08:10 – 1:16:27
Modeling Limits, Global Coordination and Country Differences
Attia questions whether models can be useful given unknown inputs. Osterholm says models are wrong but can still show what might happen under assumptions. They discuss the WHO's response, global resource competition and demographic explanations for differences across countries.
- •Osterholm says all models are wrong, though some are useful
- •Osterholm notes the lack of intelligence for predicting the next hotspots
- •He criticizes the WHO for encouraging a belief that containment would work
- •There is no global mechanism to allocate tests and N95s
- •Differences among Italy, Germany and Korea are largely demographic
- 1:16:27 – 1:22:29
Repurposed Drugs and Closing Message
Attia asks about repurposed drugs such as hydroxychloroquine, and Osterholm says he is focused on epidemiology but agrees with Attia's reading of the French study. He expects therapy information sooner than vaccines. He closes by stressing that the numbers are people and that the country will get through this.
- •Osterholm agreed that the non-randomized French study is hard to interpret
- •Systems are being set up to collect meaningful data on therapies
- •He expects therapy answers sooner than a vaccine
- •Many people will soon know someone seriously ill or who has died
- •He says we will get through this, and the question is how
